Neutropenia in Patients Treated with Rituximab

To the Editor: Rituximab is effective in B-cell lymphomas either as a single agent or combined with chemotherapy. Its toxic effects are generally mild and transient. 1 , 2 We report eight cases of acute and severe neutropenia that occurred 8 to 23 weeks after the administration of rituximab for non-...

Full description

Bibliographic Details

Published in:	The New England journal of medicine Vol. 348; no. 26; pp. 2691 - 2694
Main Authors:	Voog, Eric, Morschhauser, Franck, Solal-Céligny, Philippe
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 26-06-2003
Subjects:	Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents - adverse effects Female Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoma, B-Cell - drug therapy Lymphoma, Non-Hodgkin - drug therapy Male Middle Aged Neutropenia - chemically induced Rituximab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!